ACHN-975

ACHN-975 is a first-in-class, selective small molecule inhibitor of LpxC (UDP-3-O-acyl-N-acetylglucosamine deacetylase), an essential enzyme in the biosynthesis of lipid A, a key component of the outer membrane in Gram-negative bacteria. By inhibiting LpxC, ACHN-975 disrupts the formation of lipid A and compromises bacterial cell wall integrity, leading to bactericidal activity. It demonstrated potent *in vitro* and *in vivo* activity against multidrug-resistant Gram-negative pathogens including *Pseudomonas aeruginosa* and *Enterobacteriaceae* species[1][3][6]. The drug was developed by Achaogen for intravenous use targeting serious infections caused by these organisms but development was discontinued after phase 1 clinical trials due to safety or efficacy concerns[4][5][8].